Ungüento de lidocaína producido por una empresa china aprobada para la venta en los Estados Unidos

El nuevo ungüento de lidocaína que la compañía china ha declarado a la FDA de EE.UU. ha sido aprobado. Esto significa que el solicitante puede producir y vender el producto en el mercado estadounidense.. Se ha determinado que el 5% El efecto terapéutico de la pomada de lidocaína es equivalente a la investigación original (RLD) ungüento de locaína listado por AstraZeneca. lidocaína, también conocida como xilocaína, is a local anesthetic. It is a derivative of cocaine, but it has no hallucinations and addictive ingredients.

actualmente, the main manufacturers in the US market include Sandoz, Amneal, Taro, Akorn, and Teligent. The sales of lidocaine ointment in the U.S. market in 2018 were approximately more than 60 million U.S. dollars. actualmente, there is no import listing of this product in China.

The FDA approval number of lidocaine ointment this time signifies that Chinese companies have the qualifications to sell the product in the U.S. market, and establishes a relevant platform and mechanism for Chinese companies to develop semi-solid preparations and drug administration routes in international businesses. It has a positive impact on the company’s expansion of the US market and improvement of company performance.